| Canagliflozin and renal outcomes in type 2 diabetes and nephropathy V Perkovic, MJ Jardine, B Neal, S Bompoint, HJL Heerspink, ... New England journal of medicine 380 (24), 2295-2306, 2019 | 5592 | 2019 |
| Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes GL Bakris, R Agarwal, SD Anker, B Pitt, LM Ruilope, P Rossing, P Kolkhof, ... New England journal of medicine 383 (23), 2219-2229, 2020 | 1899 | 2020 |
| Cardiovascular events with finerenone in kidney disease and type 2 diabetes B Pitt, G Filippatos, R Agarwal, SD Anker, GL Bakris, P Rossing, A Joseph, ... New England Journal of Medicine 385 (24), 2252-2263, 2021 | 1069 | 2021 |
| Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial D De Zeeuw, R Agarwal, M Amdahl, P Audhya, D Coyne, T Garimella, ... The Lancet 376 (9752), 1543-1551, 2010 | 910 | 2010 |
| Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States R Agarwal, AR Nissenson, D Batlle, DW Coyne, JR Trout, DG Warnock The American journal of medicine 115 (4), 291-297, 2003 | 755 | 2003 |
| Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial R Thadhani, E Appelbaum, Y Pritchett, Y Chang, J Wenger, H Tamez, ... Jama 307 (7), 674-684, 2012 | 693 | 2012 |
| Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial GL Bakris, R Agarwal, JC Chan, ME Cooper, RT Gansevoort, H Haller, ... Jama 314 (9), 884-894, 2015 | 636 | 2015 |
| Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis R Agarwal, G Filippatos, B Pitt, SD Anker, P Rossing, A Joseph, P Kolkhof, ... European heart journal 43 (6), 474-484, 2022 | 612 | 2022 |
| Role of home blood pressure monitoring in overcoming therapeutic inertia and improving hypertension control: a systematic review and meta-analysis R Agarwal, JE Bills, TJW Hecht, RP Light Hypertension 57 (1), 29-38, 2011 | 536 | 2011 |
| Antiproteinuric effect of oral paricalcitol in chronic kidney disease R Agarwal, M Acharya, JIN Tian, RL Hippensteel, JZ Melnick, P Qiu, ... Kidney international 68 (6), 2823-2828, 2005 | 519 | 2005 |
| Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial J Lv, H Zhang, MG Wong, MJ Jardine, M Hladunewich, V Jha, ... Jama 318 (5), 432-442, 2017 | 508 | 2017 |
| Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial GL Bakris, B Pitt, MR Weir, MW Freeman, MR Mayo, D Garza, Y Stasiv, ... Jama 314 (2), 151-161, 2015 | 490 | 2015 |
| Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial P Alborzi, NA Patel, C Peterson, JE Bills, DM Bekele, Z Bunaye, RP Light, ... Hypertension 52 (2), 249-255, 2008 | 481 | 2008 |
| Dry-weight reduction in hypertensive hemodialysis patients (DRIP) a randomized, controlled trial R Agarwal, P Alborzi, S Satyan, RP Light Hypertension 53 (3), 500-507, 2009 | 464 | 2009 |
| Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine R Agarwal, P Kolkhof, G Bakris, J Bauersachs, H Haller, T Wada, ... European heart journal 42 (2), 152-161, 2021 | 418 | 2021 |
| Prognostic role of ambulatory blood pressure measurement in patients with nondialysis chronic kidney disease R Minutolo, R Agarwal, S Borrelli, P Chiodini, V Bellizzi, F Nappi, ... Archives of internal medicine 171 (12), 1090-1098, 2011 | 379 | 2011 |
| Research priorities for heart failure with preserved ejection fraction: national heart, lung, and blood institute working group summary SJ Shah, BA Borlaug, DW Kitzman, AD McCulloch, BC Blaxall, R Agarwal, ... Circulation 141 (12), 1001-1026, 2020 | 373 | 2020 |
| Rapid, fluorimetric–liquid chromatographic determination of malondialdehyde in biological samples R Agarwal, SD Chase Journal of Chromatography B 775 (1), 121-126, 2002 | 359 | 2002 |
| Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease R Agarwal, N Vasavada, NG Sachs, S Chase Kidney international 65 (6), 2279-2289, 2004 | 340 | 2004 |
| Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo … R Agarwal, P Rossignol, A Romero, D Garza, MR Mayo, S Warren, J Ma, ... The Lancet 394 (10208), 1540-1550, 2019 | 324 | 2019 |
George BakrisProfessor The University of Chicago MedicineEmail verificata su uchicago.edu